1 Min Read
Feb 21 (Reuters) - Amphastar Pharmaceuticals Inc said on Tuesday that the U.S. Food and Drug Administration had rejected its application to market an intranasal version of the drug naloxone, which is designed to stop or reverse the effects of an opioid overdose.
The FDA's complete response letter identifies issues including user human factors study and device evaluation, the company said.
Amphastar already sells naloxone in pre-filled syringes. (Reporting by Natalie Grover in Bengaluru)